JP Morgan maintains Agios Pharmaceuticals at Neutral, lowers price target to $30 from $34
JP Morgan kept its Neutral rating on Agios Pharmaceuticals but reduced its price target to $30 from $34, an 11.8% decrease. The new target suggests a 4.3% upside from the Nov 19 close of $28.76.

